John Volpone
Fortuna: 1 M $ al 31/05/2026
Fortuna: 1 M $ al 31/05/2026
John Volpone is currently Chief Operating Officer at X4 Pharmaceuticals, Inc. Formerly, Mr. Volpone was Director-Business Development at ZymoGenetics, Inc. and Senior Vice President-Strategic Operations at.
CTI BioPharma Corp.
Education includes an undergraduate degree from the University of Washington and an MBA from Seattle University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
X4 PHARMACEUTICALS, INC. 0,31 % | 29/10/2025 | 289.881 ( 0,31 % ) | 1 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Director de Operaciones | 16/09/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| CTI BIOPHARMA CORP. | Oficial de Recursos Humanos | 01/10/2023 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
| Empresas privadas | 5 |
|---|---|
CTI BioPharma Corp.
CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology Engages in acquisition, development and commercialization of novel targeted therapies for blood-related cancers | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Health Technology |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seattle University
Seattle University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.